

Embargoed: 0700hrs 18 July 2007

Akers Biosciences, Inc.
("ABI" or the "Company")

Directors Shareholding & Additional Listing

Akers Biosciences, Inc. which develops, manufactures, and supplies rapid, point of care screening and testing products announces that several of its directors have, on 17 July 2007, increased their shareholdings in the Company by way of a subscription to New Ordinary shares. Every member of the board has now, since the publication of the Company's financial results on 26 June 2007, either invested in the Company via the purchase of shares or converted their fees into shares.

David Wilbraham has invested £25,000 by way of a subscription to 250,000 New Ordinary Shares at yesterday's closing price of 10 pence. Mr. Wilbraham's shareholdings now total 868,000 common shares, representing 1.36% of the total issued share capital of the Company.

Dr. Raymond Akers has invested \$130,000 by way of a subscription to 635,697 New Ordinary Shares at yesterday's closing price of 10 pence. Dr. Akers' shareholdings, including his immediate family, now total 7,902,702 common shares, representing 12.42% of the total issued share capital of the Company.

Thomas A. Nicolette has converted \$16,875 of fees into 82,518 New Ordinary Shares at yesterday's closing price of 10 pence. Mr. Nicolette's shareholdings now total 656,017 common shares, representing 1.03% of the total issued share capital of the Company.

Edward Wampold has converted \$14,600 of fees into 71,394 New Ordinary Shares at yesterday's closing price of 10 pence. Mr. Wampold's shareholdings now total 249,394 common shares, representing 0.39% of the total issued share capital of the Company.

Daniel Seckinger, MD has converted \$30,000 of fees into 146,699 New Ordinary Shares at yesterday's closing price of 10 pence. Dr. Seckinger's shareholdings now total 514,888 common shares, representing 0.8% of the total issued share capital of the Company.

The Company has also issued 184,350 New Ordinary Shares to an advisor in lieu of fees.

Application has been made to the London Stock Exchange for 1,370,658 New Ordinary Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to trading, such admission expected to take place on 23 July 2007.

The exchange rate used for these transactions was \$2.045:£1.00.

Enquiries:

Thomas A. Nicolette, President & CFO
Akers Biosciences, Inc.
Tel. 001 856 848 8698

Ben Simons
Hansard Group
Tel. 020 7245 1100

Xavier de Mol
Bridgewell
Tel. 020 7003 3000
END